First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

Abstract Background Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-la...

Full description

Bibliographic Details
Main Authors: Francesca Faustini, Nicky Dunn, Nastya Kharlamova, Malin Ryner, Annette Bruchfeld, Vivianne Malmström, Anna Fogdell-Hahn, Iva Gunnarsson
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Arthritis Research & Therapy
Subjects:
Rituximab
Anti-drug antibodies (ADA)
Systemic lupus erythematosus
ANCA-associated vasculitis
Disease activity
B cell counts
Online Access:https://doi.org/10.1186/s13075-021-02589-6

Internet

https://doi.org/10.1186/s13075-021-02589-6

Similar Items